Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Hämäläinen, Päivi ^a   Saltevo, Juha ^b   Kautiainen, Hannu ^c   Mäntyselkä, Pekka ^c   Vanhala, Mauno ^d  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b CENTRAL FINLAND CENTRAL HOSPITAL   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Erythropoietin; Ferritin; Hemoglobin; Metabolic syndrome

Indexed keywords

ERYTHROPOIETIN; FERRITIN; GLUCOSE; HAPTOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFERRIN RECEPTOR;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION RESEARCH; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; ERYTHROPOIETIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FERRITINS; FINLAND; GLUCOSE METABOLISM DISORDERS; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; RECEPTORS, TRANSFERRIN; UP-REGULATION;

EID: 84866671332     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-116     Document Type: Article

References (33)

1. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444(7121):881-887. 10.1038/nature05488, 17167477.
2. Hermans MP, Ahn SA, Rousseau MF. log(TG)/HDL-C is related to both residual cardiometabolic risk and beta-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 2010, 9:88. 10.1186/1475-2840-9-88, 3020173, 21156040.
3. Kang HT, Linton JA, Shim JY. Serum ferritin level is associated with the prevalence of metabolic syndrome in Korean adults: the 2007-2008 Korean National Health and Nutrition Examination Survey. Clin Chim Acta 2012, 413(5-6):636-641.
4. Lecube A, Hernandez C, Pelegri D, Simo R. Factors accounting for high ferritin levels in obesity. Int J Obes (Lond) 2008, 32(11):1665-1669.
5. Sun L, Franco OH, Hu FB, Cai L, Yu Z, Li H, Ye X, Qi Q, Wang J, Pan A, Liu Y, Lin X. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese. J Clin Endocrinol Metab 2008, 93(12):4690-4696. 10.1210/jc.2008-1159, 18796516.
6. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, Corrocher R. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005, 28(8):2061-2063. 10.2337/diacare.28.8.2061, 16043762.
7. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992, 72(2):449-489.
8. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009, 58(3):718-725. 2646071, 19074987.
9. Regazzetti C, Peraldi P, Gremeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S. Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 2009, 58(1):95-103. 10.2337/db08-0457, 2606898, 18984735.
10. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009, 68(4):370-377. 10.1017/S0029665109990206, 19698203.
11. Vanhala M, Saltevo J, Soininen P, Kautiainen H, Kangas AJ, Ala-Korpela M, Mantyselka P. Serum omega-6 polyunsaturated fatty acids and the metabolic syndrome: a longitudinal population-based cohort study. Am J Epidemiol 2012, 176(3):253-260. 10.1093/aje/kwr504, 22791741.
12. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
13. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54(8):2277-2286. 10.2337/diabetes.54.8.2277, 16046292.
14. Lohsoonthorn V, Jiamjarasrungsi W, Williams MA. Association of hematological parameters with clustered components of metabolic syndrome among professional and office workers in Bangkok, Thailand. Diabetes Metab Syndr 2007, 1(3):143-149. 10.1016/j.dsx.2007.05.002, 2699274, 19543435.
15. Muraki I, Tanigawa T, Yamagishi K, Sakurai S, Ohira T, Imano H, Kiyama M, Kitamura A, Sato S, Shimamoto T, Konishi M, Iso H, . CIRCS Investigators Nocturnal intermittent hypoxia and metabolic syndrome; the effect of being overweight: the CIRCS study. J Atheroscler Thromb 2010, 17(4):369-377. 10.5551/jat.3319, 20103974, CIRCS Investigators.
16. Cahan C, Decker MJ, Arnold JL, Goldwasser E, Strohl KP. Erythropoietin levels with treatment of obstructive sleep apnea. J Appl Physiol 1995, 79(4):1278-1285.
17. Calvin AD, Somers VK, Steensma DP, Rio Perez JA, van der Walt C, Fitz-Gibbon JM, Scott CG, Olson LJ. Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin. Eur J Heart Fail 2010, 12(4):354-359. 10.1093/eurjhf/hfq005, 2844758, 20335353.
18. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, Ballantyne CM, Hoogeveen RC, Harris ZL, Pankow JS. A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2007, 165(9):1047-1054. 10.1093/aje/kwk093, 17284722.
19. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004, 291(6):711-717. 10.1001/jama.291.6.711, 14871914.
20. He M, Workalemahu T, Manson JE, Hu FB, Qi L. Genetic determinants for body iron store and type 2 diabetes risk in US men and women. PLoS One 2012, 7(7):e40919. 10.1371/journal.pone.0040919, 3397952, 22815867.
21. Zuliani G, Volpato S, Galvani M, Ble A, Bandinelli S, Corsi AM, Lauretani F, Maggio M, Guralnik JM, Fellin R, Ferrucci L. Elevated C-reactive protein levels and metabolic syndrome in the elderly: the role of central obesity data from the InChianti study. Atherosclerosis 2009, 203:626-632. 10.1016/j.atherosclerosis.2008.07.038, 2710530, 18845301.
22. Lu B, Yang Y, Yang Z, Feng X, Wang X, Zhang Z, Hu R. Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol 2010, 9:92. 10.1186/1475-2840-9-92, 3020174, 21167068.
23. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839. 10.2337/diacare.23.12.1835, 11128362.
24. den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salome PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol 2012, 11:25. 10.1186/1475-2840-11-25, 3359236, 22417460.
25. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110(7):1037-1044. 151151, 12370282.
26. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117(17):4425-4433. 10.1182/blood-2011-01-258467, 3099567, 21346250.
27. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, Saint-Paul MC, Huet PM, Sadoul JL, Gugenheim J, Srai SK, Tran A, Le Marchand-Brustel Y. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006, 131(3):788-796. 10.1053/j.gastro.2006.07.007, 16952548.
28. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340(6):448-454. 10.1056/NEJM199902113400607, 9971870.
29. Quaye IK. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008, 102(8):735-742. 10.1016/j.trstmh.2008.04.010, 18486167.
30. Chiellini C, Santini F, Marsili A, Berti P, Bertacca A, Pelosini C, Scartabelli G, Pardini E, Lopez-Soriano J, Centoni R, Ciccarone AM, Benzi L, Vitti P, Del Prato S, Pinchera A, Maffei M. Serum haptoglobin: a novel marker of adiposity in humans. J Clin Endocrinol Metab 2004, 89(6):2678-2683. 10.1210/jc.2003-031965, 15181041.
31. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990, 75(9):1870-1876.
32. Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis 1997, 30(4):532-541. 10.1016/S0272-6386(97)90313-9, 9328369.
33. Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Guzman G, Holterman AX, Braunschweig C. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity (Silver Spring) 2010, 18(7):1449-1456.